Rockefeller scientists engineer next-generation antibody to replace IVIG therapy

Intravenous immunoglobulin (IVIG) therapy involves infusing patients with naturally occurring IgG antibodies to treat autoimmune conditions. With origins dating back to the 1950s, IVIG is currently FDA-approved for four diseases but…

Continue Reading